CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.

CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells. Oncol Rep. 2018 Aug 10;: Authors: Gao F, Wang X, Chen S, Xu T, Wang X, Shen Y, Dong F, Zhong S, Shen Z Abstract Poor response and chemotherapy resistance to cisplatin (DDP)‑based therapy frequently lead to treatment failure in advanced bladder cancer; however the underlying mechanism is extremely complex and unclear. Furthermore, cancerous inhibitor of protein phosphatase 2A (CIP2A), a recently identified human oncoprotein, has been shown to play important regulatory roles in cancer cell survival. The present study aimed to investigate the correlation of CIP2A with sensitivity to DDP in bladder cancer cells. In the present study, knockdown of CIP2A was performed using short hairpin‑RNA. IC50 determination was used to estimate the chemosensitivity of cells to DDP. Apoptosis and DNA damage indicators were tested in vitro and in vivo to clarify the role of CIP2A in enhancing DDP sensitivity. We observed that CIP2A knockdown enhanced DDP sensitivity. CIP2A depletion accelerated the process of DNA damage caused by DDP treatment. Furthermore, DDP triggered inhibition of CIP2A by preventing AKT Ser473 phosphorylation. In vivo, CIP2A suppression increased the cytotoxicity of DDP, which resulted in a decrease in the subcutaneous tumor growth in a xenograft mouse model. Our findings revealed that the mechanism underlying the invo...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Related Links:

Conditions:   Bladder Cancer;   Chemotherapy Effect Intervention:   Combination Product: neoadjuvant chemotherapy with cisplatine Sponsors:   University Hospital, Rouen;   Institut Curie;   APHP Recruiting
Source: - Category: Research Source Type: clinical trials
CONCLUSIONS: According to our analysis, NSRH surgery after NAC via balloon occluded arterial infusion brings beneficial results to patients with bulky IB2 to IIB cervical cancers. PMID: 31497250 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
CONCLUSIONS: IGABT using Vienna II applicator allows for appropriate target coverage in tumors extending into DP/LPW at the time of BT. Clinical use is feasible and results in good local control, DFS and OS with moderate rate of acute and late ≥G3 toxicity. PMID: 31495516 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
Authors: Stabile A, Muttin F, Zamboni S, Moschini M, Gandaglia G, Fossati N, Dell'Oglio P, Capitanio U, Cucchiara V, Mazzone E, Bravi CA, Mirone V, Montorsi F, Briganti A Abstract Introduction: A considerable proportion of patients are still found with nodal involvement when considering prostate (PCa), bladder (BCa) and renal cancer (RCC). This scenario is often related to poorer oncological outcomes, but evidence supporting this correlation remain scarce or controversial. Areas covered: A review was conducted to provide updated evidence in the field of pathological nodal involvement in PCa, BCa, and RCC. Nodal-sta...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
We report a benchmarking approach to estimate the optimal rate of perioperative CT for muscle ‐invasive bladder cancer (MIBC).MethodsThe Ontario Cancer Registry and linked treated records were used to identify neoadjuvant and adjuvant CT rates among patients with MIBC during 2004 ‐2013. Monte Carlo simulation was used to estimate the proportion of observed rate variation that could be due to chance alone. The criterion‐based benchmarking approach was used to explore whether social and health‐system factors were associated with CT rates. We also used the “pared‐mean ” approach to identify a benchmark p...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
ConclusionWe defined three pre-operative risk classes. Our results indicate that patients with a cT3 –T4 disease are those who might benefit more from NAC whereas those with T2 single disease should be those to whom NAC probably shouldn’t be proposed. Given the high rate of understaging in BCa patients, NAC can be proposed in selected cases of cT2/multifocal disease.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
Objectives: Higher facility surgical volume predicts for improved outcomes in patients with muscle-invasive bladder cancer (MIBC) who undergo radical cystectomy. We investigated the association between facility radiotherapy (RT) case volume and overall survival (OS) for patients with MIBC who received bladder-preserving RT, and the relationship with adherence to National Comprehensive Cancer Network (NCCN) guidelines for bladder preservation. Methods: The National Cancer Database was used to identify patients diagnosed with nonmetastatic MIBC from 2004 to 2015 and received RT at the reporting center. Facility case vol...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
Abstract Cernumidine (CER) is a guanidinic alkaloid isolated from Solanum cernuum's leaves. In this work, we investigated the cytotoxicity, chemosensitizing effect of cernumidine to cisplatin (cDDP) and the possible mechanism of action of the combination on bladder cancer cells. Cernumidine showed cytotoxicity and could sensitize bladder cancer cells to cisplatin. The combination of CER+cDDP inhibited cell migration on T24 cells. CER+cDDP down-regulated MMP-2/9 and p-ERK1/2, while it increased EGFR activity corroborating the observed cell migration inhibition. Down-regulation of Bcl-2 and up-regulation pro-apoptot...
Source: Chemistry and Biodiversity - Category: Biochemistry Authors: Tags: Chem Biodivers Source Type: research
We agree that the wide variability in postoperative chemotherapy use observed in our study underscores the need to increase guideline-consistent care for nonmuscle invasive bladder cancer. The physician factors we examined – including physician age, years employed at our institution, specialty training in oncology, and experience treating bladder cancer – did not explain the treatment variability. As Dr. Schroeck noted, other physician factors, such as the level of concern about side effects or awareness of and ag reement with guidelines, may be important contributors to treatment variability.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
The authors report on a retrospective cohort study of 5386 patients diagnosed with nonmuscle-invasive bladder cancer (NMIBC) at Kaiser Permanente Southern California between 2001 and 2015. They find that 41% of patients received any intravesical therapy. Use of postoperative intravesical chemotherapy was rarer (given to 17%), but increased over time. There was substantial variation in use of intravesical therapy across urologists. The variation was greatest for use of postoperative intravesical chemotherapy, with 45% of the observed variation explained by the treating urologist.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Study